Article Details

Baird Has Just Reaffirmed $202 Target Price Per Share on Sarepta Therapeutics (NASDAQ:SRPT ...

Retrieved on: 2018-06-21 18:07:30

Tags for this article:

Click the tags to see associated articles and topics

Baird Has Just Reaffirmed $202 Target Price Per Share on Sarepta Therapeutics (NASDAQ:SRPT .... View article details on hiswai:

Excerpt

<div><b>Benchmark Capital</b> Advisors holds 1.01% or 17,250 shares in its portfolio. Voloridge Inv Mngmt Ltd reported 165,966 shares stake. First Trust Advisors ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo